Financial PerformanceAytu experienced its first quarter of net income profitability due to improved operations and financial performance.
Revenue DiversificationAytu BioPharma, Inc. signs commercialization agreement for Canada, diversifying revenue stream in future years.
Strategic PartnershipsAytu announced an exclusive agreement with Lupin Pharma Canada to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada, with minimal cost to Aytu, ensuring most revenue will be pure margin.